Company:  ARRAY BIOPHARMA INC (ARRY)
Form Type:  8-K
Filing Date:  6/10/2013 
CIK:  0001100412 
Address:  3200 WALNUT STREET 
City, State, Zip:  BOULDER, Colorado 80301 
Telephone:  (303) 381-6600 
Fiscal Year:  06/30 
Last Trade
Last Trade: 
$4.09  
Change: 
0.29 (7.63%)  
Trade Time: 
Apr 24  
Market Cap: 
$513.12M
Description of Business
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and is generating data to support our upcoming Phase 3 / pivotal trial decisions. Novartis International Pharmaceutical Ltd. began a Phase 3 trial evaluating Array-invented MEK162 in NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in BRAF-mutant melanoma in 2013. In addition, Array began a Phase 3 trial evaluating MEK162 in low-grade serous ovarian cancer under the License Agreement with Novartis in June 2013. AstraZeneca, PLC began a pivotal trial with Array-invented selumetinib in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer in 2013. Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 1 BUSINESS AND OPERATIONS
      Item 1.01. Entry into a Material Definitive Agreement.
    SECTION 2 FINANCIAL INFORMATION
      Item 2.03 Creation of a Direct Financial Obligation ...
    SECTION 8 OTHER EVENTS
      Item 8.01 Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURE
    EXHIBIT INDEX
  EXHIBIT 1.1
  EXHIBIT 4.1
  EXHIBIT 4.2
  EXHIBIT 5.1
  EXHIBIT 5.2
  EXHIBIT 10.1
  EXHIBIT 99.1
  EXHIBIT 99.2
BROKERAGE PARTNERS